Skip to main content

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Investor Investigation Over Possible Securities Laws Violations

  • If you purchased shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Site Members can sign up for company wide alerts

Investigation Overview

August 2, 2012 (Update) -- On August 1, 2012, after the market closed, Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that the Center for Biologics Evaluation and Research (CBER) of the FDA has issued a complete response letter for Baxter's HyQ Biologics License Application. Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) dropped from $$8.61 per share on August 1, 2012, to $...



You must register (for free) or login to view the entire investigation.